Sugi Predict

Sugi Predict / Compounds / SCHEMBL5425525

SCHEMBL5425525

SCHEMBL5425525

N=C(NC(=O)C=Cc1ccccc1)NC(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 7/20 0.54
▸ HDAC1 Q13547 7/20 0.54
▸ HDAC2 Q92769 6/20 0.54
▸ HDAC4 P56524 5/20 0.54
▸ HDAC8 Q9BY41 5/20 0.54
▸ HDAC6 Q9UBN7 5/20 0.54
▸ MMP1 P03956 3/20 0.54
▸ MMP2 P08253 3/20 0.54
▸ MMP9 P14780 3/20 0.54
▸ HTT P42858 1/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ KMT2A Q03164 1/20 0.51
▸ HDAC7 Q8WUI4 4/20 0.50
▸ HDAC9 Q9UKV0 4/20 0.50
▸ HDAC5 Q9UQL6 4/20 0.50
▸ HDAC10 Q969S8 3/20 0.50
▸ HDAC11 Q96DB2 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5425520 1.00 HDAC3 (0.54) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL15121428 0.90 HDAC2 (0.66) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL15121430 0.90 HDAC2 (0.66) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL7666658 0.89 MAPT (0.66) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL143083 0.89 MAPT (0.66) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL6933112 0.81 ALDH1A1 (0.57) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL5672865 0.81 HDAC3 (0.58) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL27689876 0.81 HDAC3 (0.58) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL5427393 0.79 MMP1 (0.70) HDAC3HDAC1HDAC2HDAC4HDAC8
SCHEMBL5427395 0.79 MMP1 (0.70) HDAC3HDAC1HDAC2HDAC4HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
CN-101111475-B Antiviral compounds and methods BIOTRON LTD 2012-09-05 — — CN disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP disclosed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885HDAC1 336/4885HDAC2 621/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885HDAC1 336/4885HDAC2 621/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HDAC3 409/4885HDAC1 400/4885HDAC2 702/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 HDAC3 262/4885HDAC1 336/4885HDAC2 621/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HDAC3 293/4885HDAC1 269/4885HDAC2 554/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HDAC3 293/4885HDAC1 269/4885HDAC2 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.